
Rockwell Medical (RMTI) Stock Forecast & Price Target
Rockwell Medical (RMTI) Analyst Ratings
Bulls say
Rockwell Medical is expected to generate a gradual improvement in gross margins and operating efficiency over the coming quarters, with financial results for the second quarter of 2026 showing increases in top-line revenue. The company has reached a balance sheet of $24.8M in cash, cash equivalents, and marketable securities, a modest increase from previous quarters. While a reverse stock split became effective on July 1, 2026, adjusting the price target to $20 from $2, the company is anticipated to bring itself into compliance with the minimum bid price requirement of $1.00 per share for continued listing on the NASDAQ exchange.
Bears say
Rockwell Medical is facing several challenges that could significantly impact its financial performance and stock performance. The company has a negative outlook due to its current valuation, which is based on a discounted cash flow assessment of only $90M. The risks associated with Rockwell Medical include a failure to achieve market traction, partnership risks, commercial setbacks, inability to control expenses, and potential equity dilution. The recent compliance with Nasdaq listing requirements is a positive development, but our Buy rating and price target of $20 per share remains unchanged.
This aggregate rating is based on analysts' research of Rockwell Medical and is not a guaranteed prediction by Public.com or investment advice.
Rockwell Medical (RMTI) Analyst Forecast & Price Prediction
Start investing in Rockwell Medical (RMTI)
Order type
Buy in
Order amount
Est. shares
0 shares